Overview Dividends

(NBIX) Neurocrine Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64125C1099

Pharmaceuticals, Neurology, Endocrinology, Neuropsychiatry, Therapeutics

NBIX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -22.36%
EPS Trend (3Y Correlation): 23.9%

NBIX Revenue

Revenue Growth (3Y CAGR): 23.14%
Revenue Trend (3Y Correlation): 96.4%

Description: NBIX Neurocrine Biosciences July 22, 2025

Neurocrine Biosciences Inc. is a biotechnology company focused on developing and marketing pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders. The companys product portfolio includes approved treatments for conditions such as tardive dyskinesia, Huntingtons disease, adrenal insufficiency, endometriosis, and uterine fibroids.

From a business perspective, Neurocrine Biosciences has a diverse pipeline of product candidates in clinical development, targeting a range of conditions including movement disorders, schizophrenia, and major depressive disorder. The companys partnerships with major pharmaceutical companies such as AbbVie and Takeda Pharmaceutical Company Limited demonstrate its ability to collaborate and leverage its research and development capabilities.

To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, product adoption rates, and clinical trial success rates are crucial. Notably, the companys return on equity (RoE) of 11.81% indicates a relatively strong ability to generate profits from shareholder equity. Additionally, the forward price-to-earnings ratio (P/E Forward) of 26.18 suggests that the market expects the company to grow its earnings in the future.

Further analysis of Neurocrine Biosciences financials and operational metrics reveals that its market capitalization stands at $13.35 billion, indicating a significant presence in the biotechnology sector. The companys ability to expand its product portfolio and successfully commercialize its treatments will be critical in driving future growth and creating value for shareholders.

NBIX Stock Overview

Market Cap in USD	14,282m
Sub-Industry	Biotechnology
IPO / Inception	1996-05-23

NBIX Stock Ratings

Growth Rating	46.9%
Fundamental	81.1%
Dividend Rating	-
Return 12m vs S&P 500	7.34%
Analyst Rating	4.48 of 5

NBIX Dividends

Currently no dividends paid

NBIX Growth Ratios

Growth Correlation 3m	62.8%
Growth Correlation 12m	33.3%
Growth Correlation 5y	74.1%
CAGR 5y	9.05%
CAGR/Max DD 3y (Calmar Ratio)	0.21
CAGR/Mean DD 3y (Pain Ratio)	0.66
Sharpe Ratio 12m	1.66
Alpha	21.87
Beta	0.212
Volatility	28.50%
Current Volume	964.7k
Average Volume 20d	684k
Stop Loss	144.4 (-3%)
Signal	-0.18

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (348.3m TTM) > 0 and > 6% of Revenue (6% = 150.6m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA -1.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 47.91% (prev 59.98%; Δ -12.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 567.3m > Net Income 348.3m (YES >=105%, WARN >=100%)

Net Debt (175.1m) to EBITDA (557.2m) ratio: 0.31 <= 3.0 (WARN <= 3.5)

Current Ratio 3.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (101.0m) change vs 12m ago -2.79% (target <= -2.0% for YES)

Gross Margin 98.49% (prev 98.28%; Δ 0.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 69.77% (prev 64.13%; Δ 5.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.18 (EBITDA TTM 557.2m / Interest Expense TTM 126.6m) >= 6 (WARN >= 3)

Altman Z'' 3.17

(A) 0.31 = (Total Current Assets 1.75b - Total Current Liabilities 546.3m) / Total Assets 3.89b

(B) 0.02 = Retained Earnings (Balance) 84.5m / Total Assets 3.89b

(D) 0.08 = Book Value of Equity 97.1m / Total Liabilities 1.20b

Total Rating: 3.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 81.07

1. Piotroski 6.50pt = 1.50

2. FCF Yield 3.85% = 1.92

3. FCF Margin 21.06% = 5.27

4. Debt/Equity 0.16 = 2.49

5. Debt/Ebitda 0.31 = 2.42

6. ROIC - WACC (= 6.35)% = 7.94

7. RoE 13.22% = 1.10

8. Rev. Trend 96.43% = 7.23

9. EPS Trend 23.95% = 1.20

What is the price of NBIX shares?

As of October 28, 2025, the stock is trading at USD 148.94 with a total of 964,731 shares traded.
Over the past week, the price has changed by +5.38%, over one month by +6.18%, over three months by +11.39% and over the past year by +28.18%.

Is Neurocrine Biosciences a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Neurocrine Biosciences (NASDAQ:NBIX) is currently (October 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.07 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NBIX is around 144.93 USD . This means that NBIX is currently overvalued and has a potential downside of -2.69%.

Is NBIX a buy, sell or hold?

Neurocrine Biosciences has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NBIX.

Strong Buy: 15
Buy: 7
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the NBIX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	170	14.1%
Analysts Target Price	170	14.1%
ValueRay Target Price	159.7	7.2%

NBIX Fundamental Data Overview October 27, 2025

Market Cap USD = 14.28b (14.28b USD * 1.0 USD.USD)
P/E Trailing = 42.6036
P/E Forward = 25.7732
P/S = 5.6903
P/B = 5.0336
P/EG = 0.2733
Beta = 0.212
Revenue TTM = 2.51b USD
EBIT TTM = 528.7m USD
EBITDA TTM = 557.2m USD
Long Term Debt = 439.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 439.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 175.1m USD (from netDebt column, last quarter)
Enterprise Value = 13.75b USD (14.28b + Debt 439.1m - CCE 975.6m)
Interest Coverage Ratio = 4.18 (Ebit TTM 528.7m / Interest Expense TTM 126.6m)
FCF Yield = 3.85% (FCF TTM 528.7m / Enterprise Value 13.75b)
FCF Margin = 21.06% (FCF TTM 528.7m / Revenue TTM 2.51b)
Net Margin = 13.88% (Net Income TTM 348.3m / Revenue TTM 2.51b)
Gross Margin = 98.49% ((Revenue TTM 2.51b - Cost of Revenue TTM 37.8m) / Revenue TTM)
Gross Margin QoQ = 98.36% (prev 98.39%)
Tobins Q-Ratio = 3.53 (Enterprise Value 13.75b / Total Assets 3.89b)
Interest Expense / Debt = 28.83% (Interest Expense 126.6m / Debt 439.1m)
Taxrate = 32.60% (52.0m / 159.5m)
NOPAT = 356.3m (EBIT 528.7m * (1 - 32.60%))
Current Ratio = 3.20 (Total Current Assets 1.75b / Total Current Liabilities 546.3m)
Debt / Equity = 0.16 (Debt 439.1m / totalStockholderEquity, last quarter 2.69b)
Debt / EBITDA = 0.31 (Net Debt 175.1m / EBITDA 557.2m)
Debt / FCF = 0.33 (Net Debt 175.1m / FCF TTM 528.7m)
Total Stockholder Equity = 2.63b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.95% (Net Income 348.3m / Total Assets 3.89b)
RoE = 13.22% (Net Income TTM 348.3m / Total Stockholder Equity 2.63b)
RoCE = 17.20% (EBIT 528.7m / Capital Employed (Equity 2.63b + L.T.Debt 439.1m))
RoIC = 13.52% (NOPAT 356.3m / Invested Capital 2.63b)
WACC = 7.18% (E(14.28b)/V(14.72b) * Re(6.80%) + D(439.1m)/V(14.72b) * Rd(28.83%) * (1-Tc(0.33)))
Discount Rate = 6.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈515.1m ; Y1≈635.4m ; Y5≈1.08b
Fair Price DCF = 185.9 (DCF Value 18.44b / Shares Outstanding 99.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 23.95 | EPS CAGR: -22.36% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.43 | Revenue CAGR: 23.14% | SUE: 2.06 | # QB: 1

Additional Sources for NBIX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle